Latest News
From the Journals
Overcoming TP53 mutation proves difficult in MCL
A new study shows disappointing results for the addition of lenalidomide to chemoimmunotherapy regimens.
Conference Coverage
Phototherapy has lasting benefit in low-risk prostate cancer
SAN FRANCISCO – A 4-year extension study shows fewer conversions to radical therapy in men with low-risk prostate cancer who receive vascular-...
From the Journals
In CRC patients, chemo yields more toxicities in women than in men
Compared with men, women receiving fluorouracil-based chemotherapy for colorectal cancer had higher rates of treatment-emergent adverse events, a...
From the Journals
Study eyes liver transplantation after Region 5 UNOS downstaging
An estimated 87% of downstaged patients were alive and recurrence free 5 years after transplantation.
From the Journals
Severity of sepsis-associated coagulopathy predicts hospital mortality
This study outlines a simplified classification scheme for coagulopathy with implications that are potentially “profound.”
Feature
CAR T therapy to enter early testing in multiple myeloma
The phase 1b/2 trial will begin enrollment in the second half of 2018.
From the Journals
Psoriasis therapy with biologics not linked to increased cancer risk
The international case-control study using registry data looked at risk in real-world clinical practice.
From the Journals
Dermatologic complaints prolong hospital stay for hematologic cancer
The results of the retrospective chart review support increased attention to dermatologic complications in cancer.
From the Journals
Sarcopenia had minor impact on hernia repair SSIs
A prospective study looks at the link between sarcopenia and ventral hernia repair outcomes.
From the Journals
Keratinocyte carcinoma added no VTE risk in cohort study
With no increased risk of VTE, clinicians should more carefully consider use of prophylactic anticoagulation in patients with squamous or basal...
News
FDA to review FLT3 agent for refractory AML
The Food and Drug Administration has granted priority review to Astellas Pharma’s gilteritinib.